Myriad Genetics, Inc.

NASDAQ:MYGN

Medical - Diagnostics & Research

Healthcare
$5.53 +3.20%

+$0.14 today

Market cap
$530.45M
Beta
1.64
P/E (TTM)
-1.1
EPS (TTM)
-$4.27
52W Low $3.53High $8.59

Volume 1.26M

Average 1.81M

MYGN Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Myriad Genetics, Inc.NASDAQ: MYGN

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $12.5M fell 13.2% year over year, in line with the -13.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.8% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.

Context

  • Depreciation & amortization amounted to 6.5% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -13.2% holds above the trailing-twelve-month pace of -13.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.5M-0.8% QoQ
Last fiscal yearDec 2025
$53.7M-12.3% YoY
LTMMar 2026
$51.8M-13.5% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-13.2%——
1 year-12.3%——
3-year CAGR+0.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
53.7M USD
Year-over-year change
-12.3%
4-year CAGR
-3.8%

Depreciation & Amortization vs competitors

How MYGN compares with its peers on the latest reported figures

  • MYGN's LTM Mar 2026 depreciation & amortization of $51.8M is the 4th highest of the 10 companies compared; the peer median is $24.2M.
  • Its year-over-year change of -13.5% is the lowest of 10, against a peer median of +0.1%.
  • Depreciation & amortization amounts to 6.2% of revenue for MYGN, versus a peer median of 7.6%.
MYGN Competitors Peer median
Depreciation & Amortization for MYGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QGENQiagen N.V.LTM Jun 2026$202.13M +7.0%-2.4%9.6%
NTRANatera, Inc.LTM Jun 2026$65.8M +87.5%+37.6%2.4%
NEONeoGenomics, Inc.LTM Jun 2026$65.46M -8.0%-0.8%8.5%
MYGNMyriad Genetics, Inc.LTM Mar 2026$51.8M -13.5%+0.6%6.2%
GHGuardant Health, Inc.LTM Sep 2026$39.23M -2.3%+3.4%3.1%
FLGTFulgent Genetics, Inc.LTM Mar 2026$24.2M +0.1%-9.6%7.6%
VCYTVeracyte, Inc.LTM Jun 2026$20.83M -9.4%-6.2%3.7%
BLLNBillionToOne, Inc.LTM Jun 2026$12.3M +13.9%—3.1%
PSNLPersonalis, Inc.LTM Mar 2026$9.83M -8.1%+6.0%15.2%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$2.34M +35.9%-25.1%119.9%
Peer median (excluding MYGN) $24.2M+0.1%-1.6%7.6%

Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue690.6M678.4M753.2M837.6M824.5M
Cost of Revenue197.6M202M236.2M252.2M247.9M
Gross Profit493M476.4M517M585.4M576.6M
Gross Margin71.4%70.2%68.6%69.9%69.9%
Research & Development81.9M85.4M88.7M113.4M106.8M
Selling, General & Admin537.8M514.7M572.9M560M537.6M
Operating Expenses683.5M617M774.4M708.9M644.4M
Depreciation & Amortization62.8M52.7M61.9M61.2M53.7M
EBITDA12.3M(84.7M)(197.4M)(59.5M)(330.9M)
EBITDA Margin1.8%-12.5%-26.2%-7.1%-40.1%
Operating Income(190.5M)(140.6M)(257.4M)(123.5M)(67.8M)
Operating Margin-27.6%-20.7%-34.2%-14.7%-8.2%
Interest Income700K2.6M2.5M1.7M1.8M
Interest Expense6.6M3.2M2.9M2.8M10.5M
Other Income / Expenses133.4M(16.9M)(4.8M)(35.5M)(327.3M)
Income Before Tax(57.1M)(140.6M)(262.2M)(123.5M)(395.1M)
Pre-Tax Margin-8.3%-20.7%-34.8%-14.7%-47.9%
Income Tax Expense(29.9M)(28.6M)1.1M3.8M(29.2M)
Net Income(27.2M)(112M)(263.3M)(127.3M)(365.9M)
Net Margin-3.9%-16.5%-35.0%-15.2%-44.4%
EPS (Basic)(0.35)(1.39)(3.18)(1.41)(3.96)
EPS (Diluted)(0.35)(1.39)(3.18)(1.41)(3.96)
Weighted Avg Shares77.71M80.58M82.8M90.6M93.3M
Weighted Avg Shares (Diluted)78M80.6M82.8M90.6M93.3M

Myriad Genetics, Inc.

NASDAQ:MYGN

Intrinsic Alpha fair value

Locked

Current Price

$5.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.